http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2406451-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_63c297f85ed186f71be9b479e82f54a5 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B17-00 |
| filingDate | 2008-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ad8312c4c6bbb79cb34a9c6745186d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57974187520180b4f527110c69b388a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b13f51545df175a6125df30ab892ce51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2001da190287b4122cfa56587616f2cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deae578c017ad39e69da62758a3559be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26c17f5452dd5b46b4ebd4e2634c20e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0665e9c2b5f12389d206233013e02d00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d780f5fc7d815084e6a47416c563fe5f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_058a9d31a255286100066e8b7969c78d |
| publicationDate | 2010-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2406451-C2 |
| titleOfInvention | Method of intraoperative intracavity hyperthermic chemotherapy in disseminated abdominal and pelvic cancer in human |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in therapy of disseminated abdominal and pelvic cancer. The method involves the preoperative patient positioning on a mattress heated to temperature 37-39°C, the removal of primary and secondary cancer foci, the installation of drainage tubes in the abdominal and pelvic cavities. Thereafter, a reservoir is created to be filled with a perfusion solution specified from dialysis solution, Ringer's solution or 5% glucose and containing Oxaliplatin in dosage 50-130 mg/m 2 or Mitomycin C in dosage 20 mg/m 2 and 5-fluorouracil in dosage 1 g/m 2 . The stage of the initiation and during hyperthermic chemotherapy involves the forced cooling of the patient's occiput and cervical great vessels. For the hyperthermic chemotherapy, the perfusion solution of temperature 43-48°C is used, and for the postoperative chemotherapy, the chemotherapeutic solution of temperature 37-38°C is introduced through the kept drainages. n EFFECT: method allows to prevent tumour cell penetration into the vascular and lymphatic bed due to combined high-temperature, sensitising and cytotoxic action of the high concentrated chemopreparations in tumour tissue. n 31 cl, 11 ex |
| priorityDate | 2008-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.